- Home
- USIO vs ALGS Comparison
USIO vs ALGS Comparison
Compare USIO & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USIO | ALGS |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.2M | 39.9M |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | USIO | ALGS |
|---|---|---|
| Price | $1.62 | $5.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $4.00 | ★ $39.33 |
| AVG Volume (30 Days) | 105.6K | ★ 117.1K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,200,535.00 | $2,186,000.00 |
| Revenue This Year | $12.15 | $32.20 |
| Revenue Next Year | $8.57 | $4.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.69 | N/A |
| 52 Week Low | $1.03 | $5.12 |
| 52 Week High | $2.02 | $13.69 |
Technical Indicators
Market Signals| Indicator | USIO | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 64.45 | 43.24 |
| Support Level | $1.35 | N/A |
| Resistance Level | $1.74 | $6.82 |
| Average True Range (ATR) | 0.11 | 0.45 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 80.00 | 33.24 |
Price Performance
Historical ComparisonAbout USIO Usio Inc.
Usio Inc is a cloud-based Fintech payment processor. The company serves multiple industry verticals with technology that facilitates payment acceptance and funds disbursement in a single, full-stack ecosystem. It provides payment acceptance through multiple payment methods, including payment facilitation, prepaid card, and electronic billing products and services to businesses, merchants, and consumers. The company's reportable operating segments are Output Solutions and Merchant Services, and these segments.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.